Ginkgo Bioworks Holdings Inc (NYSE: DNA) has experienced a rise in its stock price by 13.21 compared to its previous closing price of 8.56. However, the company has seen a fall of -13.48% in its stock price over the last five trading days. prnewswire.com reported 2025-01-13 that Collaboration leverages Ginkgo’s cell engineering and screening platform to enhance the potency and persistence of Universal Cells’ iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 /PRNewswire/ — Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo’s capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
Company’s 36-month beta value is 1.10.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for DNA is 36.49M, and currently, short sellers hold a 20.21% ratio of that floaft. The average trading volume of DNA on January 15, 2025 was 1.28M shares.
DNA’s Market Performance
DNA’s stock has seen a -13.48% decrease for the week, with a -6.19% drop in the past month and a 33.11% gain in the past quarter. The volatility ratio for the week is 10.96%, and the volatility levels for the past 30 days are at 11.93% for Ginkgo Bioworks Holdings Inc The simple moving average for the past 20 days is -1.73% for DNA’s stock, with a -38.71% simple moving average for the past 200 days.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at 6.62% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.95% of loss for the given period.
Volatility was left at 11.93%, however, over the last 30 days, the volatility rate increased by 10.96%, as shares surge +4.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.92% upper at present.
During the last 5 trading sessions, DNA fell by -11.61%, which changed the moving average for the period of 200-days by -78.66% in comparison to the 20-day moving average, which settled at $9.87. In addition, Ginkgo Bioworks Holdings Inc saw -1.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $9.15 back on Jan 15 ’25. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $906 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $8.92 during a trade that took place back on Jan 14 ’25, which means that Che Austin is holding shares at $883 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 0.64 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -2.99. The total capital return value is set at -0.43. Equity return is now at value -63.51, with -37.13 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -6358.49.
Currently, EBITDA for the company is -821.29 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.72. The receivables turnover for the company is 9.31for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.79.
Conclusion
In a nutshell, Ginkgo Bioworks Holdings Inc (DNA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
